Terns Pharmaceuticals, Inc. Income Tax Provision

Income Tax Provision of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Income Tax Provision growth rates and interactive chart. The actual income tax expense for the applicable year.


Highlights and Quick Summary

  • Income Tax Provision for the quarter ending March 31, 2022 was $21 Thousand (a -95.17% decrease compared to previous quarter)
  • Year-over-year quarterly Income Tax Provision increased by 50.0%
  • Annual Income Tax Provision for 2021 was $508 Thousand (a -37.52% decrease from previous year)
  • Annual Income Tax Provision for 2020 was $813 Thousand (a -4165.0% decrease from previous year)
  • Annual Income Tax Provision for 2019 was $-20 Thousand (a -70.15% decrease from previous year)
  • Twelve month Income Tax Provision ending March 31, 2022 was $490 Thousand (a -3.54% decrease compared to previous quarter)
  • Twelve month trailing Income Tax Provision decreased by -43.42% year-over-year
Trailing Income Tax Provision for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$490 Thousand $508 Thousand $784 Thousand $866 Thousand
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Income Tax Provision of Terns Pharmaceuticals, Inc.

Most recent Income Tax Provisionof TERN including historical data for past 10 years.

Interactive Chart of Income Tax Provision of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Income Tax Provision for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.02
2021 $0.44 $0.02 $0.01 $0.04 $0.51
2020 $0.71 $0.1 $0.81
2019 $0.0 $-0.02
2018 $-0.07

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.